Clinical Trial Detail

NCT ID NCT02982941
Title Enoblituzumab (MGA271) in Children With B7-H3-expressing Solid Tumors
Recruitment Active, not recruiting
Gender both
Phase Phase I
Variant Requirements yes
Sponsors MacroGenics
Indications

rhabdomyosarcoma

neuroblastoma

Advanced Solid Tumor

Ewing sarcoma

nephroblastoma

osteosarcoma

Therapies

MGA271

Age Groups: adult child

Additional content available in CKB BOOST